Shashank Shetty, MD.DM 🇮🇳

Nephrologist and Transplant Physician #Critical Care & Transplant Nephrology#Utd fan🔴 Student

[Sanjeev Sethi @SethiRenalPath]

Thus, each 🎯 antigen is rather specific.

EXT and NCAM1- autoimmune diseases

NELL1 and THSD7A- tumors

NELL1- herbal medicines, lipoic acid

FAT1- hematopoietic stem cell transplant

CNTN1- demyelinating polyneuropathy

NDNF- Syphilis

And now-

PCSK6- NSAIDs

[NEJM @NEJM]

Aldosterone has long been a pharmacologic target for the treatment of hypertension. However, a new small-molecule drug called baxdrostat inhibits aldosterone synthase in patients with treatment-resistant hypertension. 1/14

[Sanjeev Sethi @SethiRenalPath]

1/6. Here is my approach to work up of the antigens in membranous nephropathy (MN). It’s not perfect. @NephRodby @GlassockJ

Start with the common (~60 %) group: This includes:
PLA2R, followed by
NELL1.

[Edgar V. Lerma 🇵🇭 @edgarvlermamd]

Finerenone: A New Frontier in Renin Angiotensin-Aldosterone System Inhibition in Diabetic Kidney Disease ca. 2021 from @AJKDonline #Nephpearls
👉🏼 https://t.co/8LVZw9Xeo0

[Shashank Shetty, MD.DM 🇮🇳 @Nephkid]

@aishaikh @GlomCon Wonderful tweetorial! Thank you for the review

[Edgar V. Lerma 🇵🇭 @edgarvlermamd]

Voclosporin: Hope on the Horizon for #Lupus Nephritis❓ from @KidneyNews February 2021 issue #Nephpearls
👉 https://t.co/oUMtmCsL1v

[Edgar V. Lerma 🇵🇭 @edgarvlermamd]

SGLT2 inhibitors in AKI from @KidneyNews February 2021 issue #Nephpearls
👉 https://t.co/oUMtmCsL1v

[ASN Publications @asnpublications]

Study looks at efficacy & safety of canagliflozin in a post hoc subgroup analysis of CREDENCE trial participants with eGFR <30 ml/min per 1.73 m2 at randomization. Findings suggest canagliflozin slowed progression of kidney disease, without increasing AKI https://t.co/bFZ9KH2M9E

[Sanjeev Sethi @SethiRenalPath]

1/1 On the other hand, 5 Qs that nephrologists ask pathologists (that a bx should answer): 1) What is the diagnosis? (etiology) 2) How active is the lesion? (pattern of injury) 3) Is there ATN? (other findings) 4) How much scarring is present? (IFTA) 5) And even should I treat?

[Sam Albadri, M.D., M.Sc. @sam_albadri]

Excellent new two discoveries by @SethiRenalPath @MayoClinicPath @MayoClinicNeph in membranous NP @ASNKidney #KidneyWk #KidneyWeek2020 @ldcornell @Justaglomerular @MPAlexanderMD @Tiff_Caza @stubob @ErikaBracamo316 @Nephro_Sparks @nephrologista @fervenzafernan1 @HennepinKidney

[Sanjeev Sethi @SethiRenalPath]

Few take home messages on new Ag: 1)EXT1/EXT2: autoimmune dis, good prognosis, 2)NELL1: Mostly primary, 2nd common Ag, segmental staining, also malignancy asso- 3)Sema3B: childhood Ag, 4)PCDH7: older pts, non-complement activating, milder 5)NCAM1-primary & autoimmune dis 6) HTRA1

[Shashank Shetty, MD.DM 🇮🇳 @Nephkid]

@ManUtd Glazers out

[Mahesha Vankalakunti 🇮🇳 @MVankalakunti]

Nice illustration of EM of #BKvirus #polyoma